Login to Your Account

Chi-Med starts phase II savolitinib combo trial in EGFR-resistant NSCLC

By Shannon Ellis
Staff Writer

Tuesday, June 21, 2016

SHANGHAI – Hutchison China Meditech Ltd. is a biopharma unwilling to leave any stone unturned with its c-Met inhibitor, savolitinib. The Nasdaq-listed, China-based company has 11 clinical trials in 17 different indications for savolitinib.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription